Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab in AAV: when and how to use it.

Literature DB >> 21878889

Rituximab in AAV: when and how to use it.

Julia U Holle, Wolfgang L Gross.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21878889 DOI： 10.1038/nrrheum.2011.131

Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543

× No keyword cloud information.

9 in total

1. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors: John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245

2. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors: Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245

Review 3. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors: Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal: Ann Rheum Dis Date: 2006-12-14 Impact factor: 19.103

4. EULAR recommendations for the management of primary small and medium vessel vasculitis.

Authors: C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani
Journal: Ann Rheum Dis Date: 2008-04-15 Impact factor: 19.103

5. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors: Mary-Jane C J Guerry; Paul Brogan; Ian N Bruce; David P D'Cruz; Lorraine Harper; Raashid Luqmani; Charles D Pusey; Alan D Salama; David G I Scott; Caroline O S Savage; Richard A Watts; David R W Jayne
Journal: Rheumatology (Oxford) Date: 2011-05-25 Impact factor: 7.580

1 in total

Review 1. Treatment of ANCA-associated vasculitis, where to go?

Authors: Cees G M Kallenberg
Journal: Clin Rev Allergy Immunol Date: 2012-12 Impact factor: 8.667

1 in total

Rituximab in AAV: when and how to use it.

1. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

2. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Review 3. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

4. EULAR recommendations for the management of primary small and medium vessel vasculitis.

5. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

6. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades.

Review 7. ANCA vasculitis: time for a change in treatment paradigm? Not yet.

8. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.

9. Wegener granulomatosis: an analysis of 158 patients.

Review 1. Treatment of ANCA-associated vasculitis, where to go?